search
Back to results

CFTR Related Pancreatitis Study

Primary Purpose

Cystic Fibrosis, CFTR Gene Dysfunction

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Beta Adrenergic Sweat Test
Sponsored by
The Hospital for Sick Children
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Cystic Fibrosis

Eligibility Criteria

4 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age : 4 years and older
  • Diagnosis: Acute recurrent pancreatitis or chronic pancreatitis
  • History: at least one of the following:

    1. Carry one or two CFTR mutations
    2. Borderline sweat chloride levels
    3. Has Family History of CF
    4. Has had positive CF Newborn screening

      Exclusion Criteria:

  • Pregnant females: will be excluded at screening.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Interventional Arm

    Arm Description

    All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.

    Outcomes

    Primary Outcome Measures

    Assessment of CFTR function using the Beta Adrenergic Sweat Secretion Test
    CFTR function assessment of patients with acute recurrent or chronic pancreatitis by using Beta adrenergic sweat test.

    Secondary Outcome Measures

    Full Information

    First Posted
    February 16, 2020
    Last Updated
    July 12, 2021
    Sponsor
    The Hospital for Sick Children
    Collaborators
    The National Pancreas Foundation
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04274413
    Brief Title
    CFTR Related Pancreatitis Study
    Official Title
    Assessing CFTR Function in Patients With CFTR Related Pancreatitis Using a Novel Sweat Test
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2021
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Due to funding and Covid-19 pandemic
    Study Start Date
    February 1, 2021 (Actual)
    Primary Completion Date
    February 1, 2021 (Actual)
    Study Completion Date
    February 1, 2021 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    The Hospital for Sick Children
    Collaborators
    The National Pancreas Foundation

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The main causes of acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) in children are defects in genes that have been associated to pancreatitis. Among these gene defects CFTR gene mutations are commonly found, 34% ARP and 23% CP . Since not every CFTR gene mutations clinically manifest, just identifying these CFTR gene mutations may not help to establish a clear role of this defect in the etiology of the individual ARP/CP. The novel beta-adrenergic sweat secretion test is a very sensitive test to detect small abnormalities in CFTR function in form of a linear gene-function relation. By identifying even mild CFTR defects, in future will help in finding the role of CFTR modulators and providing treatment to these patients.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cystic Fibrosis, CFTR Gene Dysfunction

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Model Description
    Evaporimeter TEWL probes, model RG-1
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Interventional Arm
    Arm Type
    Experimental
    Arm Description
    All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
    Intervention Type
    Combination Product
    Intervention Name(s)
    Beta Adrenergic Sweat Test
    Intervention Description
    In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab. Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site. Under the first probe, injection atropine will be given in one small area of the skin. Under the second probe, first injection carbachol will be given in one small area of the skin. Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine. Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded.
    Primary Outcome Measure Information:
    Title
    Assessment of CFTR function using the Beta Adrenergic Sweat Secretion Test
    Description
    CFTR function assessment of patients with acute recurrent or chronic pancreatitis by using Beta adrenergic sweat test.
    Time Frame
    60 mins

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    4 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age : 4 years and older Diagnosis: Acute recurrent pancreatitis or chronic pancreatitis History: at least one of the following: Carry one or two CFTR mutations Borderline sweat chloride levels Has Family History of CF Has had positive CF Newborn screening Exclusion Criteria: Pregnant females: will be excluded at screening.

    12. IPD Sharing Statement

    Learn more about this trial

    CFTR Related Pancreatitis Study

    We'll reach out to this number within 24 hrs